Will 2014 Be the Year We Win the War Against the Flu?

With flu season hitting its peak, will this revolutionary new vaccine from the biopharmaceutical sector deliver improved results?

Jan 19, 2014 at 11:50AM

The joy of the holiday season has passed, and the perils of tax season are still three months away -- which can only mean one thing: We're right in the heart of flu season!

Although flu season doesn't have an official start or end date, January and February are historically the two months out of the year when influenza cases in hospitals and doctor's offices will peak.

Flu Cases
Source: Centers for Disease Control and Prevention.

It's estimated, according to the Centers for Disease Control and Prevention, that anywhere between 5% and 20% of all U.S. residents will come down with the flu in a given year. That works out to approximately 16 million to 63 million adults and children developing the flu annually and resulting in a range of 3,000 to 49,000 deaths each year (based on data collected between 1976 and 2006). 

Overall, that makes the flu pretty benign in terms of a death rate relative to infection rate, but it can still present a serious concern to infants, the elderly, and people with compromised immune systems. Plus, having the flu isn't any fun, which most of us can testify to from personal experience at one time or another.

This is why biopharmaceutical companies spend millions each year investing into research that could help better treat and/or prevent the influenza virus. There is, of course, one somewhat obvious drawback to that research.

Influenza: Where sciences and guessing go hand-in-hand
The drawback in question relates to the fact that scientific researchers don't know with any exactness what strain of flu virus is going to be dominant in any given year. They can only go off early flu cases and historical records and make their best estimation of which strains are expected to account for the majority of influenza cases in a given year. Because it can take weeks for a biopharmaceutical company to make the necessary dosing (in some cases up to 60 million doses) for the country, these vaccines are made well in advance of when flu season strikes (usually around June or July). Like meteorologists, researchers are often pretty close with their expectations, but every once in a while they're way off.

Researchers and biopharmaceutical companies last year did a pretty good job, according to CDC estimates. The mid-season update for 2012-2013 demonstrated a vaccine effectiveness, or VE, of 56% for all age groups, with a VE of 47% against influenza A strains and 67% against influenza B strains. Those with weaker or compromised immune systems, such as the elderly, demonstrated a weaker VE. 

Although we're early in the game, so to speak, it appears as if 2013-2014's flu season is going to again be active, with the weekly Influenza Surveillance Report from the CDC pointing to significantly higher influenza-like illness outpatient visits, or ILIs, through the second week of 2014.

Ili Map
Source: Centers for Disease Control and Prevention.

Nationwide, the proportion of ILI outpatient visits was 3.6% relative to a baseline figure of 2%. This means it could be another very active year for flu vaccine manufacturers -- especially for those that have a new trick up their sleeve this year! 

The new flu-fighting weapon
What's most notable about the 2013-2014 flu season, and what I suspect could give flu vaccine manufacturers and those who get a flu shot an edge over previous years, is a new formulation of the vaccine, dubbed a quadrivalent, that aims to provide immune response detection to two influenza A strains and two influenza B strains.

In years past, biopharmaceutical companies have focused on trivalent vaccines that feature two influenza A strains -- often the more prominent strain -- and one influenza B strain. Just like swinging at a baseball and trying to hit a home run, having more strains within the vaccine formulation gives the body a greater chance at an effective vaccine response -- in exchange for a slightly higher cost, of course.

There is, though, no favoritism offered by the CDC when it comes to trivalent or quadrivalent flu vaccines. The CDC does not recommend one formulation over the other -- it merely urges people to get their flu shot. However, it appears likely to me that the quadrivalent would offer better protection against influenza B group viruses. In 2013-2014, roughly 30 million to 32 million of the 138 million to 145 million influenza vaccines produced will be quadrivalent.

Fluzone

Source: CDC, Wikimedia Commons.

Who could benefit
There are three primary biopharmaceutical companies that could be big beneficiaries of this push toward quadrivalent vaccines: AstraZeneca (NYSE:AZN), GlaxoSmithKline (NYSE:GSK), and Sanofi (NYSE:SNY).

AstraZeneca's primary quadrivalent play is FluMist, the Food and Drug Administration's only approved nasal spray, which it acquired when it purchased MedImmune. FluMist has never quite lived up to its billing, however, because the cost of the nasal spray relative to simply getting a shot hasn't translated well with consumers. Despite that disappointment, FluMist still delivered an estimated $162 million in sales last year, and given its convenience factor could still be a viable quadrivalent option in 2014.

GlaxoSmithKline will always be considered an important quadrivalent vaccine manufacturer, since Fluarix was the very first quadrivalent vaccine approved by the FDA, in December 2012. In other words, Glaxo sort of set the stage for the other biopharma companies, which they quickly followed. What should really be of interest to shareholders and influenza patients is its FluLaval quadrivalent, which brought in about $375 million in sales last year. With the company beefing up its production of FluLaval quadrivalent vaccines in 2014, expect to see a sizable revenue jump here.

However, no company may see a bigger top- and bottom-line benefit than Sanofi, whose FluZone vaccine outsold every other influenza vaccine, combined, last year! FluZone has a number of clear-cut benefits to patients, including a transdermal patch that reduces the length of the needle by 90% to make it less painful, and comes in six separate dosing options, which is music to the ears of physicians, who understand that one size does not always fit all. I fully expect that Sanofi's FluZone, which will be sold in both trivalent and quadrivalent formulations, will have a fantastic year.

The opportunity to get rich doesn't present itself often, but this top stock could be one of those instances!
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers